Physician profile
James Dimuzio
NPI 1306822424
$2,742.65
in general payments reported to CMS, 2019-2025
19 companies · $701 in 2025
The $701 reported for 2025 was more than what 79% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.71 · 2020: $200 · 2021: $385 · 2022: $409 · 2023: $401 · 2024: $562 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.62 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $636.70 | 2024-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Genzyme Corporation | $592.95 | 2019-2025 | |
| Acclarent, INC | $317.62 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $254.11 | 2021-2025 | Dupixent |
| Optinose US, INC. | $211.51 | 2020-2025 | |
| Aerin Medical INC. | $178.66 | 2019-2025 | |
| Intersect Ent, INC. | $133.51 | 2019-2021 | |
| Oticon Medical, LLC | $94.02 | 2021 | |
| Glaxosmithkline, LLC. | $90.94 | 2021-2025 | Nucala |
| Merck Sharp & Dohme LLC | $41.05 | 2023-2025 | Keytruda |
| Amgen INC. | $34.00 | 2025 | |
| Smith+Nephew, INC. | $29.84 | 2020 | |
| Novartis Pharmaceuticals Corporation | $27.69 | 2021 | |
| Medtronic, INC. | $20.62 | 2024 | Nuvent |
| Inspire Medical Systems, INC. | $19.91 | 2025 | Inspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $16.69 | 2025 | Xhance |
| Stryker Corporation | $16.07 | 2024 | Audion Et Dilation System |
| Allergan, INC. | $14.86 | 2020 | |
| Forte Bio-Pharma LLC | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dimuzio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.